The gastrointestinal (GI) tract and liver represent common target organs of coronavirus disease 2019 (COVID-19).[@bib1] A recent meta-analysis showed that 17.6% of patients with COVID-19 had gastrointestinal symptoms.[@bib2] Digestive system involvement is associated with a poor disease course.[@bib3]

Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are commonly used in patients with hypertension. A recent landmark study including 1128 patients with COVID-19 with hypertension showed that inpatient use of ACEI/ARB was associated with lower risk of mortality compared with ACEI/ARB nonusers.[@bib4] We aimed to determine the impact of ACEI/ARB use on the digestive system in patients with COVID-19 with hypertension.

Methods {#sec1}
=======

A retrospective study investigating the clinical and virologic characteristics of COVID-19 between January 28, 2020, and April 8, 2020 was performed. All patients with COVID-19 cared for by the rescue medical team of the First Affiliated Hospital of Sun Yat-sen University were recruited consecutively from the West Campus of Wuhan Union Hospital.

The primary outcome was the comparison of the rate of GI symptoms and abnormal liver function of patients with COVID-19 with hypertension who did vs did not use ACEI/ARB during the disease course. The secondary outcome was the prognosis of these patients, including complications, mortality, and time to discharge from hospital.

The definition of GI symptoms included abdominal pain, diarrhea, nausea, and vomiting.[@bib3] The definition of abnormal liver function was alanine aminotransferase level of \>40 U/L, aspartate aminotransferase level of \>40 U/L, or total bilirubin level of \>20 μmol/L.

The cumulative probabilities of GI involvement and abnormal liver function were estimated using the Kaplan-Meier method. Statistical significance was set at *P* \< .05.

Results {#sec2}
=======

Participants {#sec2.1}
------------

This study cohort included 204 consecutive patients with COVID-19. Among the 100 participants with hypertension, 31 were classified as the ACEI/ARB group, and the remaining 69 were classified as the non-ACEI/ARB group. The characteristics of the ACEI/ARB group vs the non-ACEI/ARB group on admission are provided in [Supplementary Table 1](#tblS1){ref-type="table"}. Comorbidities, including GI disease, chronic obstructive pulmonary disease, coronary heart disease, diabetes, and chronic renal disease, were comparable between the 2 groups (all *P* \> .05). The rate of the critical/severe type was comparable between the ACEI/ARB group and the non-ACEI/ARB group (87.1% vs 87.0%; *P* \> .05).

Compared to the ACEI/ARB group, the non-ACEI/ARB group had a higher prevalence of dyspnea and bilateral lung lesion at presentation. In terms of in-hospital treatment, the ACEI/ARB group had a higher percentage of using a beta-blocker (32.3% vs 4.3%; *P* \< .001) and a lower percentage of systemic corticosteroid use (9.7% vs 37.7%; *P* \< .01) than patients in the non-ACEI/ARB group ([Supplementary Table 1](#tblS1){ref-type="table"}).

Primary Outcome {#sec2.2}
---------------

As shown in [Figure 1](#fig1){ref-type="fig"} *A*, patients taking ACEI/ARB had a significantly lower risk of GI symptoms (38.7% vs 58%; *P* = .031) and abnormal liver function (22.6% vs 42%; *P* = .043) throughout the disease course. On admission, there was a trend toward, although not significantly, a lower rate of GI symptoms in the ACEI/ARB group compared to the non-ACEI/ARB group (12.9% \[4/31\] vs 29% \[20/69\]; *P* = .082). The spectrum of GI symptoms includes diarrhea (6.5% vs 14.5%), nausea and vomiting (9.7% vs 11.6%), and abdominal pain (2.9% vs 6.5%) in the ACEI/ARB group vs non-ACEI/ARB group, respectively.Figure 1(*A*) Prognosis of patients COVID-19 with hypertension in the ACEI/ARB and non-ACEI/ARB groups. (*B*, *C*) Kaplan-Meier curves for the cumulative probability of (*B*) gastrointestinal involvement and (*C*) abnormal liver function during 30-day follow-up in the ACEI/ARB or non-ACEI/ARB groups among 100 patients with COVID-19 with hypertension. IQR, interquartile range.

As shown in [Figure 1](#fig1){ref-type="fig"} *B* and *C*, the cumulative rate of GI involvement was significantly lower in the ACEI/ARB group vs non-ACEI/ARB group (*P* = .032; hazard ratio, 1.95; 95% confidence interval, 1.11--3.42). Furthermore, the risk of abnormal liver function was also significantly lower in the ACEI/ARB group vs the non-ACEI/ARB group (*P* = .033; HR, 2.15; 95% CI, 1.07--4.27).

Secondary Outcome {#sec2.3}
-----------------

As shown in [Figure 1](#fig1){ref-type="fig"} *A*, during the follow-up period, 11 of the included 100 patients with hypertension died. The risk of all-cause mortality was significantly lower in the ACEI/ARB group vs non-ACEI/ARB group (0% \[0/31\] vs 15.9% \[11/69\]; *P \<* .01).

Among patients using ACEI/ARB, only 2 (6.4%) patients used invasive ventilation; 2 (6.4%) patients had GI bleeding; and no patient had sepsis, multiple organ dysfunction syndrome (MODS) or need for intensive care. All but 2 patients were discharged within a median of 33 (25.5--39.5) days of hospital stay. On the contrary, in the non-ACEI/ARB group, 11 (16.4%) patients were on mechanical ventilation (2 on noninvasive and 9 on invasive ventilation), 1 (1.5%) patient had sepsis, 1 (1.5%) patient had multiple organ dysfunction syndrome, 4 (9%) patients had GI bleeding, and 3 (4.5%) patients needed intensive care. Forty-six (66.7%) patients were discharged with a median of 36.5 (22.8--43.8) days of hospital stay.

Discussion {#sec3}
==========

The present study explored GI system involvement with the use of ACEI/ARB among patients with COVID-19 with hypertension. Our result showed that inpatient treatment with ACEI/ARB was associated with lower risk of GI system involvement compared with ACEI/ARB nonusers. Recently, it was reported that the serum level of angiotensin II (ACE-2) is significantly elevated in patients with COVID-19 and exhibits a linear positive correlation to viral load and abnormal liver function.[@bib5] Activation of the RAS can cause widespread endothelial dysfunction and varying degrees of multiple organ (heart, kidney, lung, and digestive system) injuries. Thus, intake of ACEI/ARB might relieve organ damage, including GI and liver injury resulting from RAS activation.

Consistent with a previous study from Zhang et al,[@bib4] our study also showed that use of ACEI/ARB was associated with lower risk of all-cause mortality. Theoretically, ACEI/ARB could up-regulate ACE-2 expression, which might increase severe acute respiratory syndrome coronavirus 2 entry into cells.[@bib4] Alternatively, increased ACE-2 activity could increase conversion of ACE-2 to angiotensin, a peptide with potentially protective anti-inflammatory properties. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections, without a firm conclusion.[@bib6] The recent statement from cardiovascular societies recommended the continuation of ACEI or ARB among patients with coexisting hypertension and COVID-19.[@bib7]

This study has certain limitations. First, because of the small sample-size, we could not detect if there was a differential effect between ACEI and ARB. Second, the differences in proportions of patients using beta-blocker and systematic corticosteroids between the ACEI/ARB and non-ACEI/ARB groups might have had an unappreciated confounding effect.

Our study showed that inpatient treatment with ACEI/ARB was associated with lower risk of digestive system involvement and lower mortality compared with ACEI/ARB nonusers in patients with COVID-19 with hypertension. Large-scale prospective cohort studies and randomized controlled trials are needed to validate the preliminary findings of our study.

Supplementary Material {#appsec1}
======================

Supplementary Table 1Characteristics of Patients With COVID-19 With Hypertension in the ACEI/ARB and Non-ACEI/ARB GroupsCharacteristicsACEI/ARB group (n = 31)Non-ACEI/ARB group (n = 69)*P*Sex14:1737:32.285Age, median (IQR)67 (62--70)67.5 (57--71).479Duration, median (IQR)**10(7--16.5)12 (8.8--16).041**Respiratory symptoms, n (%)20 (64.5)48 (69.6).359 Fever24 (77.4)53 (76.8).850 Cough/expectoration15 (48.4)37 (53.6).528 Shortness of breath5 (16.1)24 (34.8).047 Chest distress3 (9.7)5 (7.2).710GI symptoms, n (%)**4 (12.9)20 (29).082** Diarrhea2 (6.5)10 (14.5).211 Vomiting3 (9.7)8 (11.6).738 Abdominal pain2 (2.9)2 (6.5).436Comorbidities on admission, n (%) Diabetes8 (25.8)20 (29).616 GI comorbidities6 (19.4)17 (24.6).513 Chronic renal diseases4 (12.9)5 (7.2).398 Coronary heart disease5 (16.1)13 (18.8).697 COPD2 (6.5)7 (10.1).524 Tumor1(3.2)4(5.8).566Laboratory examination on admission, median (IQR) AST27.5 (24-30.75)31.5 (22-49).103 ALT34 (20-48)32 (18-59.7).409 TBIL11.6 (7.8-13.9)11.4 (7.4-17.1).153 CRP23.97 (4-43)24 (6.7-62.5).406 Lymphocyte1.16 (0.8-1.6)1.01 (0.73-1.3).109 D-dimer0.76 (0.26-2.39)0.96 (0.58-2.1).609Severity, n (%).613 Mild0 (0)2 (2.9) Moderate4 (12.9)7 (10.1) Severe24 (77.4)38 (55.1) Critical3 (9.7)22 (31.9)In-hospital management, n (%) Antiviral drug19 (61.3)52 (75.4).093 Antibiotic drug17 (54.8)40 (58).650 Antifungal medications04 (5.8).077 Systemic corticosteroids**3 (9.7)26 (37.7).003** Lipid-lowering drug8 (25.8)10 (14.5).196 CCB15 (48.4)24 (34.8).237 Beta-blocker**10 (32.3)3 (4.3)\<.001** Alpha-blocker1 (3.2)1 (1.4).573 ACEI4 (12.9)0 ARB27 (87.1)0 Renal replacement therapy1 (3.2)5 (7.2).416 Noninvasive ventilation**05 (7.2).048** Invasive ventilation2 (6.5)9 (13).287[^2]
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